Idarubicina Accord (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA, disrupting the double‑helix structure, and inhibits topoisomerase II, which prevents the resealing of DNA strands during replication. This leads to accumulation of DNA breaks, triggering apoptosis of rapidly dividing leukemic cells and reducing tumor burden.

The dosing regimen for Idarubicina Accord is individualized by the treating physician based on disease type, patient age, body surface area, and organ function. Clinicians calculate the appropriate intravenous dose and schedule according to established oncology protocols and patient‑specific factors.

Idarubicina Accord is contraindicated during pregnancy and lactation because anthracyclines can cause fetal harm and are excreted in breast milk. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided throughout treatment and for a period recommended by the prescriber.

To order Idarubicina Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Idarubicina (idarubicin) is structurally related to daunorubicin but has a higher lipophilicity, allowing better cellular uptake and potentially greater antileukemic activity. It shares the same class‑related toxicities, such as cardiotoxicity and myelosuppression, but may be preferred in certain regimens due to its pharmacokinetic profile.

Idarubicina Accord must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should not be frozen or shaken. During preparation, use aseptic technique, keep the solution in the original container, and discard any unused portion after the recommended in‑use period.

Idarubicina is given as an intravenous infusion, typically diluted in a compatible carrier solution. The infusion rate and duration are determined by the treating oncologist and nursing staff, following institutional protocols to monitor for infusion‑related reactions and ensure patient safety.

The most serious adverse risks include cardiotoxicity (which can lead to irreversible heart failure), severe myelosuppression resulting in neutropenia or thrombocytopenia, and life‑threatening infections. Prompt monitoring of cardiac function, blood counts, and infection signs is essential throughout therapy.

Idarubicina should not be used in patients with known hypersensitivity to idarubicin or other anthracyclines, those with severe pre‑existing cardiac dysfunction (e.g., left‑ventricular ejection fraction < 50 %), uncontrolled active infections, or in pregnant or nursing women unless no alternative exists.